Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLCG1 | P19174 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.47 |
| ▸ | CA2 | P00918 | 3/20 | 0.46 |
| ▸ | POLB | P06746 | 7/20 | 0.46 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.46 |
| ▸ | CTDSP1 | Q9GZU7 | 5/20 | 0.44 |
| ▸ | GRK2 | P25098 | 3/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.42 |
| ▸ | RECQL | P46063 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | MMP1 | P03956 | 1/20 | 0.42 |
| ▸ | MMP2 | P08253 | 1/20 | 0.42 |
| ▸ | MMP9 | P14780 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5446197 | 0.88 | PLCG1 (0.57) | PLCG1KMT2ACA2POLBHSD11B1 | |
| SCHEMBL165340 | 0.82 | PLCG1 (0.67) | PLCG1KMT2ACA2POLBHSD11B1 | |
| SCHEMBL19127744 | 0.80 | PLCG1 (0.64) | PLCG1KMT2ACA2POLBHSD11B1 | |
| SCHEMBL426162 | 0.80 | ALDH1A1 (0.52) | KMT2ACA2POLBHSD11B1LMNA | |
| SCHEMBL13586189 | 0.78 | PLCG1 (0.61) | PLCG1KMT2ACA2POLBHSD11B1 | |
| SCHEMBL8775111 | 0.78 | ALDH1A1 (0.42) | PLCG1KMT2ACA2POLBLMNA | |
| SCHEMBL6353755 | 0.78 | GAA (0.57) | KMT2ACA2LMNATDP1ALDH1A1 | |
| SCHEMBL1149166 | 0.78 | ALDH1A1 (0.69) | KMT2ACA2LMNAALDH1A1CYP3A4 | |
| SCHEMBL5974400 | 0.78 | CA2 (0.53) | KMT2ACA2LMNAALDH1A1CYP3A4 | |
| SCHEMBL1938871 | 0.78 | CA2 (0.64) | PLCG1KMT2ACA2POLBHSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100311729-A1 | Substituted imidazopyridazines and pyrrolopyrimidines as lipid kinase inhibitors | CAPRARO HANS-GEORG | 2010-12-09 | — | — | US | disclosed |
| EP-2155202-A2 | 3,6-DISUBSTITUTED-IMIDAZO[1,2-B]PYRIDAZINES AND 3,5-DISUBSTITUTED PYRAZOLO[1,5-A]PYRIMIDINES AS PHOSPHATIDYLINOSITOL-3-KINASE INHIBITORS | Novartis Ag (CH) | 2010-02-24 | — | — | EP | disclosed |
| WO-2008138889-A2 | 3, 6-DISUBSTITUTED-IMIDAZO [1, 2-B] PYRIDAZINES AND 3, 5-DISUBSTITUTED PYRAZOLO[1, 5-A] PYRIMIDINES AS PHOSPHATIDYLINOSITOL-3-KINASE INHIBITORS | NOVARTIS AG (CH) | 2008-11-20 | — | — | WO | disclosed |
| EP-0841323-B1 | Method for producing arylvinylsulfone | SUMITOMO CHEMICAL CO (JP) | 2003-03-05 | — | — | EP | disclosed |
| US-5902905-A | Method for producing arylvinylsulfone | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1999-05-11 | — | — | US | disclosed |
| EP-0841323-A2 | Method for producing arylvinylsulfone | SUMITOMO CHEMICAL COMPANY LIMITED (JP) | 1998-05-13 | — | — | EP | disclosed |
| US-4724235-A | N-(arylthioalkyl)-N'-(aminoalkyl)ureas useful in the treatment of arrhythmia | A. H. ROBINS COMPANY, INCORPORATED (US) | 1988-02-09 | — | — | US | disclosed |
| US-4597902-A | TREATMENT OF CARDIAC ARRHYTHMIAS | A. H. ROBINS COMPANY, INCORPORATED (US) | 1986-07-01 | — | — | US | disclosed |
| EP-0066415-B1 | N-(ARYLTHIOALKYL)-N'-(AMINOALKYL)UREAS | A.H. ROBINS COMPANY, INCORPORATED (US) | 1985-10-02 | — | — | EP | disclosed |
| EP-0066415-A2 | N-(arylthioalkyl)-N'-(aminoalkyl)ureas | A.H. ROBINS COMPANY, INCORPORATED (US) | 1982-12-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100311729-A1 | Substituted imidazopyridazines and pyrrolopyrimidines as lipid kinase inhibitors | PI4KA, PIP5K1B, PIP4K2A | PLCG1 144/4885KMT2A 3440/4885CA2 3368/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.